Indaptus Therapeutics, Inc.
corporate_fare Company Profile
Indaptus Therapeutics, Inc. (NASDAQ:INDP) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 34 items for INDP at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-10, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for INDP spans 8-K, 424B5, 424B3, S-3.
Recent high-impact activity:
- Indaptus Secures $24M via Private Placement at Nasdaq Minimum Price
- Indaptus Launches $100M At-the-Market Offering with H.C. Wainwright
- Indaptus Registers 58.9M Shares for Resale — 44% of Outstanding Now Tradable
- Indaptus Registers 58.9M Shares for Resale — 44% of Outstanding
- Indaptus Halts Decoy20, Pivots to Strategic Alternatives with $11.6M Cash
Financial Snapshot
Short Interest & Short Volume
1.00 days to coverFINRA reported short interest of 916,352 shares in INDP as of the September 15, 2026 settlement, a 331.5% increase from the prior period — about 1.0 days to cover at its recent average daily volume. On October 2, 2026, 63.1% of INDP volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for INDP, detected from its recent SEC filings · based on capital-structure filings through 2026-09-10.
Clerical Correction to Dilution Table · No Shares Sold Under ATM
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →